Meet Kazia’s management team and hear about paxalisib, Kazia’s lead programme

Published on 9 May 2022

Kazia Therapeutics (KZIA) is an oncology-focused drug development company. Its drug candidates are designed to treat cancers which are poorly served by existing therapies.

In this video, James Garner, CEO, introduces Kazia’s expanding US management team: chief medical officer, John Friend, and chief financial officer, Karen Krumeich. John and Karen highlight their experience and what interested them about Kazia. As part of a three-episode Edison TV series, the team also discusses Kazia’s lead asset, paxalisib, a highly potent, small molecule, brain-penetrant inhibitor of PI3K/mTOR, and when we can expect final data from the ongoing Phase III study. Stay tuned for the next video, which focuses on paxalisib beyond glioblastoma.

Share this with friends and colleagues